Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Like many Chinese Americans my age and older, I have fond memories of going to San Francisco’s now-scarce Chinese banquet halls to mark milestones and celebrations. My parents had a 600-person wedding ...

Some situations in life are zero-sum. On Super Bowl Sunday, two teams take the field but only one will emerge victorious, Vince Lombardi Trophy in hand. In a presidential election, only one candidate ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Bitcoin whales are accumulating at a record pace amid almost $5.8 billion in capitulation losses, signaling a potential bullish reversal. Bitcoin whales and mid-sized holders are aggressively ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Ripple Labs Inc. is leading an effort to raise at least $1 billion to accumulate XRP, the digital token linked to the company, in a sign that the recent market tumult has not stopped cryptocurrency ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...